Rapalogix Health

Rapalogix is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, focused on developing novel therapeutics that target the mechanistic target of rapamycin, also known as mTOR, for the treatment of cancer and other serious diseases. Founded in 2018 by Nathanael Gray and David Sabatini, the company is pioneering the dev... elopment of next-generation mTOR inhibitors designed to overcome the limitations of existing therapies by achieving more complete and selective inhibition of mTOR signaling pathways. Rapalogix's lead program focuses on RMC-5552, a selective mTORC1 inhibitor designed to provide improved efficacy and tolerability compared to first-generation rapalogs and ATP-competitive mTOR inhibitors. The company's proprietary platform leverages deep scientific understanding of mTOR biology and medicinal chemistry expertise to create differentiated small molecule inhibitors that can selectively modulate mTOR complex 1 and mTOR complex 2 activity. Rapalogix addresses significant unmet medical needs in oncology and other therapeutic areas where dysregulated mTOR signaling plays a critical role in disease progression. The company has raised venture capital funding to advance its pipeline through preclinical and clinical development stages. Rapalogix was founded by leading scientists in the mTOR field, with co-founder David Sabatini recognized for groundbreaking research on mTOR signaling and co-founder Nathanael Gray known for expertise in kinase inhibitor design and chemical biology, positioning the company at the forefront of next-generation mTOR-targeted therapeutics.Read More